Genmab — November 2019
-
Rimelig stor omsætning på de første tre timer.
-
Drug repurposing - featuring ofatumumab https://www.pharmaceutical-technology.com/features/drug-repurposing-all-rounder/
-
Vi har Q&A på fredag.
-
@Sukkeralf. Hele markedet er i risk on mode siden primo oktober. Se evt. mit link i går kl. 20:12 (det kan være farligt at stå udenfor)
-
Primo oktober var investor sentiment det ringeste siden finanskrisen, der findes ikke bedre købsindikator. Financial Times har lavet statistik over dette. I dette århundrede har vi haft et tocifret tilfælde af lignende dårlig investor sentiment, og hver gang har det medført et stort aktierally de efterfølgende 12 måneder!!!
-
Som Warren Buffet siger "be greedy when others are fearful"
-
Halozyme Announces HALO-301 Phase 3 Study Fails To Meet Primary Endpoint. Halozyme intends to halt development activities for PEGPH20 and implement an organizational restructuring to focus its operations solely on its ENHANZE
drug delivery technology. https://www.halozyme.com/investors/news-releases/news-release-details/2019/Halozyme-Announces-HALO-301-Phase-3-Study-Fails-To-Meet-Primary-Endpoint/default.aspx https://www.halozyme.com/investors/news-releases/default.aspx
ser spændende ud - jeg er allerede all in men kan spæde til med CFDer
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind